Johnson & Johnson (JNJ) · Oct 13, 2026 · Earnings

Johnson & Johnson earnings edge past estimates as Stelara erodes

Beat — Adjusted EPS $2.59 vs ~$2.52 consensus

Johnson & Johnson earnings narrowly beat adjusted EPS expectations, but Stelara declines, litigation charges and softer margins complicate the growth story.

Johnson & Johnson is in a replacement-growth phase: its Innovative Medicine business is trying to offset the loss of exclusivity for STELARA with TREMFYA, newer oncology therapies and neuroscience products, while MedTech supplies steadier but slower growth. The company’s current strategy is explicitly centered on those two businesses and on shifting growth toward newer medicines and medical-device platforms.

The quarter narrowly cleared the market’s operating hurdle. Adjusted diluted EPS was $2.59, ahead of the published consensus of roughly $2.52, while sales of $25.399 billion were only slightly above the roughly $25.38 billion expectation. That is a small beat, not a broad acceleration: adjusted EPS still declined 7.5% year over year, and adjusted net earnings fell 6.8% (Income Statement; Adjusted Net Earnings reconciliation).

MetricQ3 2026Q3 2025 / expectationRead
Sales$25.399B$23.993B; ~$25.38B consensus5.9% growth; slight beat (Income Statement)
Adjusted diluted EPS$2.59$2.80; ~$2.52 consensus7.5% year-over-year decline; narrow beat (Adjusted Net Earnings reconciliation)
Reported diluted EPS$0.09$2.1295.8% decline, distorted by litigation expense (Income Statement)
Innovative Medicine sales$16.757B$15.563B7.7% reported; 7.9% operational growth (Segment results — Innovative Medicine)
MedTech sales$8.642B$8.430B2.5% reported and operational growth (Segment results — MedTech)

The replacement engine is working, but the old franchise is shrinking faster. Innovative Medicine’s growth was led by TREMFYA, which rose 68.3% worldwide, alongside strong growth in DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE, SPRAVATO and CAPLYTA. But STELARA fell 54.4% worldwide and the broader Immunology category declined 3.6% for the first nine months, leaving the new-product ramp as an offset rather than a clean expansion of earnings power (Segment results — Innovative Medicine).

MedTech remains a stabilizer, not a growth breakout. The segment grew 2.5% in the quarter, with better momentum in Shockwave, surgical products and cardiovascular devices, but Surgery declined 0.6% worldwide and international operational sales were essentially flat. That mix supports portfolio stability, though it does not yet compensate for the pharmaceutical portfolio’s patent-cycle disruption (Segment results — MedTech).

The reported collapse is mostly litigation noise, but the underlying margin pressure is real. J&J recorded $5.519 billion of litigation-related expense in the quarter, driving reported net earnings down to $210 million and reported diluted EPS to $0.09. Even excluding special items, gross margin fell to 68.1% from 69.6%, while research and development expense rose 26.7%, showing that investment in replacement products is carrying a near-term earnings cost (Income Statement; Adjusted Net Earnings reconciliation).

Bottom line: This was a narrow operating beat that validates J&J’s newer-product replacement strategy, but it does not erase the Stelara hole or the pressure on adjusted earnings. The business is progressing, though the improvement is incremental rather than decisive.

What to watch next

Orthopaedics restructuring completion, Q4 2026

Original filing on SEC EDGAR

Johnson & Johnson earnings edge past estimates as Stelara erodes | JNJ Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.